Gilead Sciences reports Q1 2026 results today against a backdrop of broad analyst conviction — but a stock that has quietly drifted lower and a short interest position that has been building steadily through April.
The Street is notably bullish heading into the print. Morgan Stanley lifted its target to $175 earlier this month, maintaining Overweight, while Citigroup raised to $165 and kept its Buy rating on April 13. Both moves follow Jefferies initiating coverage in March with a $180 target and a Buy. The consensus clusters around $158, roughly 23% above the current price of $128.84 — a gap that implies the market has not fully accepted the bull thesis. Bears point to real vulnerabilities: heavy reliance on the HIV and hepatitis portfolio, rising competition, patent exposure, and a history of mixed clinical trial results. Barclays, which initiated at Equal-Weight in February with a $155 target, reflects the more cautious end of the spectrum.
Short interest has risen sharply but does not yet signal a crowded short. SI has climbed nearly 24% over the past month to 1.8% of the free float — a meaningful acceleration, with the bulk of the jump arriving in mid-April in a single session. Yet borrow conditions remain almost frictionless: cost to borrow is running at just 0.40%, easing over both the past week and month, and availability in the lending market is wide open. With the ORTEX short score at 32.7, this is far from the territory where squeeze dynamics become relevant.
Options traders are modestly more cautious than usual, though the signal is mild. The put/call ratio is 0.57, just above its 20-day average of 0.54 — a z-score of 0.66, well within normal bounds. That is a long way from the near-1.28 reading that marks the defensive extreme of the past year. On the price side, GILD is down 4% over the past month and shed another 3% on the week, underperforming peers AMGN and VRTX, which lost roughly 1.5% each. The insider picture adds a mild note of caution: the CEO sold $1.4M in shares in late March, and the CFO has sold in multiple tranches since — all low-significance transactions, but net insider selling of around $40M over 90 days is a detail bears will notice.
The Q1 report is less a test of whether Gilead's HIV franchise is holding and more a test of whether the oncology pipeline — the strategic rationale behind recent acquisitions — is generating enough momentum to close the gap between where the stock trades and where a cohort of bullish analysts thinks it belongs.
See the live data behind this article on ORTEX.
Open GILD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
